Amgen Inc. is a multinational biotechnology and pharmaceutical company. It produces various drugs, including Neulasta, which prevents infections for patients undergoing cancer chemotherapy, Enbrel, a necrosis blocker for the treatment of autoimmune diseases. Focusing on molecular biology and biochemistry, Amgen aims at developing health care through recombinant DNA technology. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen
Unlock to Claim this listing
Add / Modify Company
3.73
Overall Excellence Rating
Industry
InsuranceCategory
Biotechnology ResearchESG/Ethical Impact
Amgen’s sustainability goals for 2027 – Where we want to be: 100% carbon neutral by 2027. Where we are: Amgen has noted a 30% reduction in water consumption since 2007. Where we want to be: An additional 40% reduction in water use by 2027. Where we are: Amgen has noted a 28% reduction in waste since 2007. We report on specific targets we’ve set for environmental conservation and improvements. We also measure our overall energy and carbon, water, waste, and sales. At Amgen, our employees bring innovation to life and make us who we are — a leader in serving patients. Our ability to deliver for patients is strengthened by attracting, retaining and promoting a diverse workforce of talented and engaged employees who believe in our mission and values. As the way people work post-pandemic continues to evolve, we are adapting how we recruit, develop and retain top talent from an array of fields and backgrounds. This includes providing employees opportunities to develop their skills to build meaningful careers. We are also taking a closer look at how we can better support the total health, safety and well-being of our staff. As of December 31, 2022, Amgen had approximately 25,200 staff members in over 50 countries, and we have had relatively low global turnover rates compared to available industry information. Following the COVID-19 pandemic, Amgen introduced a flexible workspace initiative that encourages eligible employees, working together with their manager, to choose the location best suited to their work. Employees who choose to work virtually part-or full-time can continue to come to an Amgen site for daily work and/or for activities that benefit from face- to-face collaboration, networking and recognition events. Amgen has a highly independent Board of Directors elected annually by a majority of our stockholders, with a lead independent director with robust responsibilities. Only independent Board members serve on key standing committees. Key standing committees of our Board include the Audit, Compensation and Management Development, Corporate Responsibility and Compliance, and the Governance and Nominating committees. Our Board of Directors is guided by our Amgen Board of Directors Corporate Governance Principles. Our Board has adopted an Amgen Board of Directors’ Code of Conduct (which applies to our Board) and a global Code of Conduct (which applies to our Board, all our employees and others conducting business on our behalf). Additionally, annual training on the global Code of Conduct is required of all our employees, and our Board participates in such training. We also have a code of ethics for senior financial officers. Amgen is a leading biotechnology company focused on developing and commercializing innovative therapies in areas like oncology, immunology, and bone health. The company’s success hinges on its strong drug pipeline, which includes both established treatments and novel therapies.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
26833300000
Website Traffic
Employee Rating
4.1
Customer Rating
3.8
Company Size
10000+
ESG Risk Rating
3



